India’s DCGI grants emergency approval to Covishield and Covaxin vaccines
In a major step forward in India’s fight against the Covid-19 pandemic, the Drugs Controller General of India…
Biocon launches generic Tacrolimus in U.S.: A gamechanger in transplant care
Find out how Biocon’s launch of generic Tacrolimus in the U.S. marks a strategic leap in affordable transplant care and global generic market expansion.
Switzerland becomes first country to grant full approval to Pfizer-BioNTech Covid-19 vaccine
Switzerland becomes the first nation to fully approve the Pfizer-BioNTech Covid-19 vaccine. Find out how Swissmedic's rigorous process could influence global vaccine confidence.
AstraZeneca wins FDA approval for Tagrisso in adjuvant treatment of early-stage NSCLC patients with EGFR mutations
Find out how AstraZeneca’s expanded FDA approval for Tagrisso is transforming early-stage lung cancer treatment standards.
Lilly begins real-world Covid-19 study of bamlanivimab in New Mexico to assess outcomes in high-risk patients
Eli Lilly begins a real-world Covid-19 study of bamlanivimab in New Mexico. Find out how mobile clinics aim to reduce hospitalizations in high-risk patients.
FDA grants emergency use authorization for Moderna’s Covid-19 vaccine: What this means for the U.S. pandemic response
Find out how Moderna’s mRNA-1273 vaccine received FDA emergency use authorization and what it means for the United States’ Covid-19 vaccination rollout.
Novartis to acquire Cadent Therapeutics in $770m deal to bolster neuropsychiatric pipeline
Find out how Novartis plans to transform neuroscience with its $770M acquisition of Cadent Therapeutics and its novel CNS treatment pipeline.
Eli Lilly to acquire Prevail Therapeutics for $1.04bn, expanding gene therapy pipeline
Eli Lilly and Company has signed a deal worth up to $1.04 billion to acquire Prevail Therapeutics, a…
EQT Partners offers $2.8bn takeover bid for Swedish pharma giant Recipharm
Swedish private equity firm EQT Partners has made a bold move in the pharmaceutical sector, offering to acquire…
AstraZeneca signs $39bn deal to acquire Alexion Pharmaceuticals
In a landmark move that’s poised to shake up the world of immunology and rare disease treatments, AstraZeneca…